QS-21: a water-soluble triterpene glycoside adjuvant
- 1 September 1998
- journal article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 7 (9) , 1475-1482
- https://doi.org/10.1517/13543784.7.9.1475
Abstract
QS-21 is a purified immunological adjuvant derived from a natural source, the bark of the tree Quillaja saponaria. It is a water soluble triterpene glycoside with amphiphilic character that can be mixed with a soluble antigen in a fully soluble vaccine formulation or combined with emulsion or mineral salt adjuvants. QS-21 has been shown to enhance antibody and cell-mediated immune responses to subunit antigens, as well as DNA vaccines in animal models. It acts as an immunostimulatory adjuvant, eliciting production of immunomodulatory cytokines, and not as an antigen depot. QS-21 is currently under clinical evaluation with various vaccines. This includes a Phase II evaluation of a QS-21 adjuvanted pneumococcal polysaccharide vaccine and a Phase III evaluation of a QS-21 adjuvanted GM2-KLH (ganglioside GM2 vaccine) immunotherapeutic product for melanoma. At present, more than 1600 individuals have received vaccines containing QS-21 adjuvant. In most studies, QS-21-containing vaccines have been well-tolerate...Keywords
This publication has 7 references indexed in Scilit:
- DNA VACCINESAnnual Review of Immunology, 1997
- A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine againstPlasmodium falciparumMalariaNew England Journal of Medicine, 1997
- Structure/Function Studies on QS-21, A Unique Immunological Adjuvant from Quillaja saponariaPublished by Springer Nature ,1996
- Structure/function studies of QS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant functionVaccine, 1995
- Monophosphoryl Lipid A as an AdjuvantPublished by Springer Nature ,1995
- Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in mice that are similar to those generated by experimental infectionVaccine, 1995
- Cholera toxin and cholera B subunit as oral—mucosal adjuvant and antigen vector systemsVaccine, 1993